Projet Mac4Me (Horizon Europe, appel à projets 2023)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Immunotherapies promise to be the major break-through in the treatment of metastatic cancer, but effectiveness is limited to few cancer types. Metastatic neuroblastoma, breast and prostate cancer, affecting approximately 300,000 EU-27 inhabitants of all age groups in 2020, respond not or very poorly to current immunotherapies. To establish more effective immunotherapies, we need to better understand the specific tumour cell-immune host interactions at the metastatic site. The Mac4Me Doctoral Network adopts an innovative, multidisciplinary and cross-sectional approach, with a unique and dedicated research training programme to equip young researchers with scientific knowledge and transferable skills that are essential for today’s great demand in both academic and non-academic sectors. Mac4Me aims to understand the tumour cell-immune host interactions at the metastatic site. with an in-depth molecular and mechanistic understanding of the immune and matrix changes induced by tumour cells. We will use innovative animal-free organ-on-chip systems, that recapitulate early metastasis formation of brain, bone and liver. The retrieved knowledge from the preclinical models will be integrated in data from established clinical metastases and AI machine learning algorithms will be applied to identify new immune targets. Mac4Me will align with patients and the general public from the very beginning thereby bringing societal expectations and patient needs into the centre of the project to pave the way for new standards for shared decision making and acceptable health care solutions. Mac4Me will prepare a next generation of young scientists to start their own career as independent researchers being equipped with scientific knowledge and personal skills and integrating participatory science as a starting point to address the societal demand for more effective treatment solutions for incurable metastatic disease, such as neuroblastoma, breast and prostate cancer.

Mots clés : metastasis, immuno oncology, macrophage targeting, ageing, matrix remodeling, prostate cancer, breast cancer, neuroblastoma, liver metastasis, bone metastasis, brain metastasis, citizen science

Participants :
- Med'Inn'Pharma (France) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de technologie de Delft (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274370.4 €
- The garvan institute of medical research charitable institution (Australie) — Partner, associated partner, Recherche, subvention : 0.0 €
- Europa uomo (Belgique) — Partner, associated partner, Autres, subvention : 0.0 €
- Peptimatrix limited (Royaume-Uni) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université Pompeu Fabra (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 251971.2 €
- European Association for Cancer Research (Royaume-Uni) — Partner, associated partner, Autres, subvention : 0.0 €
- Université de Berne (Suisse) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université d'Helsinki (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 286488.0 €
- Grasp - guiding researchers & advocates to scientific partnerships (Etats-Unis) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université Érasme de Rotterdam (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 548740.8 €
- Phialogics gmbh (Allemagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université Érasme de Rotterdam (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274370.4 €
- Hôpital de l'Université d'Oslo (Norvège) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 297748.8 €
- React4life spa (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 259437.6 €
- Royal College of Surgeons in Ireland (Irlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 572976.0 €
- Genevia technologies oy (Finlande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 286488.0 €
- École polytechnique de Milan (Italie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- University College Dublin (Irlande) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Nottingham (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université technologique de Dresde (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 521078.4 €
- Université de Milan-Bicocca (Italie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Faron Pharmaceutical (Finland) (Finlande) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de Heidelberg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 521078.4 €
- Université de Tampere (Finlande) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €